Pharmacodynamic Effects of Vorapaxar in Prior Myocardial Infarction Patients Treated With Potent Oral P2Y(12) Receptor Inhibitors With and Without Aspirin: Results of the VORA‐PRATIC Study

BACKGROUND: Vorapaxar as an adjunct to dual antiplatelet therapy (DAPT) reduces thrombotic events in patients with prior myocardial infarction at the expense of increased bleeding. Withdrawal of aspirin has emerged as a bleeding reduction strategy. The pharmacodynamic effects of vorapaxar with poten...

Descripción completa

Detalles Bibliográficos
Autores principales: Franchi, Francesco, Rollini, Fabiana, Faz, Gabriel, Rivas, Jose Ramon, Rivas, Andrea, Agarwal, Malhar, Briceno, Maryuri, Wali, Mustafa, Nawaz, Ahmed, Silva, Gabriel, Shaikh, Zubair, Maaliki, Naji, Fahmi, Kerolos, Been, Latonya, Pineda, Andres M., Suryadevara, Siva, Soffer, Daniel, Zenni, Martin M., Baber, Usman, Mehran, Roxana, Jennings, Lisa K., Bass, Theodore A., Angiolillo, Dominick J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7428520/
https://www.ncbi.nlm.nih.gov/pubmed/32306797
http://dx.doi.org/10.1161/JAHA.120.015865

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7428520/
https://www.ncbi.nlm.nih.gov/pubmed/32306797
http://dx.doi.org/10.1161/JAHA.120.015865

Ejemplares similares